Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities. Raza, A., Reeves, J. E., Feldman, E. J., Deeg, H., Dreisbach, L., Schiffer, C. A., Shammo, J. M., Klimek, V. M., Greenberg, P. L., Bennett, J. M., DeWald, G. W., Zeldis, J. B., Wride, K., Schmidt, M., Knight, R. D., List, A. F. AMER SOC HEMATOLOGY. 2006: 78A

View details for Web of Science ID 000242440000251